Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085450" target="_blank" >RIV/00216224:14110/15:00085450 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/65269705:_____/15:00063842
Výsledek na webu
<a href="http://dx.doi.org/10.1056/NEJMoa1509388" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1509388</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1509388" target="_blank" >10.1056/NEJMoa1509388</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Popis výsledku v původním jazyce
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trialto compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. METHODS We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil. The primary end point was progression-free survival as assessed by an independent review committee. RESULTS The median age of the patients was 73 years. During a median follow-up period of 18.4 months, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (haz
Název v anglickém jazyce
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Popis výsledku anglicky
BACKGROUND Chronic lymphocytic leukemia (CLL) primarily affects older persons who often have coexisting conditions in addition to disease-related immunosuppression and myelosuppression. We conducted an international, open-label, randomized phase 3 trialto compare two oral agents, ibrutinib and chlorambucil, in previously untreated older patients with CLL or small lymphocytic lymphoma. METHODS We randomly assigned 269 previously untreated patients who were 65 years of age or older and had CLL or small lymphocytic lymphoma to receive ibrutinib or chlorambucil. The primary end point was progression-free survival as assessed by an independent review committee. RESULTS The median age of the patients was 73 years. During a median follow-up period of 18.4 months, ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil (haz
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FD - Onkologie a hematologie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
New England Journal of Medicine
ISSN
0028-4793
e-ISSN
—
Svazek periodika
373
Číslo periodika v rámci svazku
25
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
13
Strana od-do
2425-2437
Kód UT WoS článku
000366461400009
EID výsledku v databázi Scopus
—